This study is looking at how a medication called abaloparatide affects bone quality in people with osteoporosis (a condition where bones become weak and brittle) who are having spinal fusion and decompression surgery for lumbar degenerative disease (problems with the lower back). Researchers want to see if abaloparatide improves bone density, as measured by a special score called VBQ, and if it helps reduce problems after surgery, like complications with the spinal hardware. You might be able to join if you are 50 or older, have osteoporosis based on certain criteria (like a fragility fracture or a low T-score), and are scheduled for this type of back surgery. The study aims to enroll 60 participants. The current status of the study is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 60 participants.

What's involved

Participants will receive 3-6 months of abaloparatide treatment and will be trained on how to apply it. They will also have presurgical assessments.

Compensation

Not stated in the trial record.

Follow-up

Bone quality will be measured at 6 weeks post-operation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.